Author

E. Antmen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cell type annotation· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Bardia· 2 shared B. S. Wittner· 2 shared D. A. Haber· 2 shared D. T. Ting· 2 shared S. Maheswaran· 2 shared V. Hasirci· 2 shared A. Buyuksungur· 1 shared A. Deshpande· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

A. Bardia

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

A. Mishra, S.-B. Huang, T. Dubash, R. Burr, B. S. Wittner, Q. E. Cunneely, V. R. Putaturo, A. Deshpande, E. Antmen, K. A. Gopinathan, K. Otani, Y. Miyazawa, J. E. Kwak, S. Y. Guay, J. Kelly, , M. Toner

This study uses high-throughput microfluidic technology to enrich CTCs from large blood volumes, enabling detailed molecular and morphological analysis of tumor cells in metastatic cancer patients.

bioRxiv · Mar 13, 2024 · PreprintBioengineering

CDKN1B (p27kip1) enhances drug tolerant persister CTCs by restricting polyploidy following mitotic inhibitors.

E. Horwitz, T. D. Dubash, A. Szabolcs, B. S. Wittner, J. Kreuzer, R. Morris, A. Bardia, B. Chirn, D. Wiley, D. Che, H. C. Russel, X. I. H. Lopez, D. B. Fox, E. Antmen, D. T. Ting, , D. A. Haber

This study identifies CDKN1B as a regulator of drug-tolerant persister CTCs by preventing polyploidy after mitotic inhibitor treatment in breast cancer.

bioRxiv · Feb 20, 2024 · PreprintCancer Biology

Loss Of Nuclear Deformability Of Breast Cancer Cells By The Disruption Of Actin Filaments

E. Antmen, U. Demirci, V. Hasirci

This study shows that disrupting actin filaments reduces nuclear deformability in breast cancer cells, preventing nuclear morphology distortions and metastasis.

bioRxiv · Nov 26, 2019Bioengineering

A 2-Compartment Bone Tumor Model for Testing the Efficacy of Cancer Drugs

A. Komez, A. Buyuksungur, E. Antmen, W. Swieszkowskic, N. Hasirci, V. Hasirci

This paper develops a 3D bone tumor model to study cell interactions, migration, and drug efficacy, finding Doxorubicin reduces Saos-2 cell viability by 7-fold in the model.

bioRxiv · Nov 4, 2019 · PreprintBioengineering